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ABSTRACT 
A small library of twelve, structurally diverse, fluoroaryl benzimidazoles was prepared using a 
simple synthetic strategy employing SNAr reactions. This allowed rapid assembly of heterocyclic 
structures containing linked and tethered fluoroaryl benzimidazoles. X-ray crystal structures of 
seven compounds were obtained including those of two macrocyclic compounds containing 21- and 
24-membered rings. Three tethered fluoroaryl benzimidazole derivatives demonstrated micromolar 
inhibition against K-562 and MCF-7 cell lines. These compounds, in addition to 1-tetrafluoropyrid-
4-yl-2-tetrafluoropyrid-4-ylsulfanyl-1H-benzimidazole, also demonstrated micromolar inhibition 
against G361 and HOS cell lines. Two of the compounds were found to activate caspases leading to 
apoptosis.  
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1. Introduction 
As part of an ongoing medicinal chemistry programme to develop synthetically accessible and 
modifiable scaffolds [1, 2, 3], the facile SNAr reaction of perfluoroarenes [4] is being employed to 
generate fluorinated heterocyclic libraries [5] for screening. SNAr reactions of perfluorinated 
aromatics occur predictably with a wide range of nucleophiles, proceed readily under mild 
conditions, and without the need for transition metal catalysis [6]. Substitution patterns available by 
stepwise replacement of fluorines are different from those afforded by electrophilic aromatic 
substitution and allow preparation of diverse structural types [7, 8]. Potential for ring formation 
with bidentate nucleophiles [9, 10], control of regiochemistry through hard/soft nucleophilic 
interactions [11, 12,], and alternative methods for promoting reaction by ultrasound [13] continue to 
attract attention. Retaining fluorine in a molecule is also desirable from a medicinal chemistry 
perspective, since fluorine can improve resistance to metabolism due to the strong C–F bond (485 
kJmol–1) while the small size (van der Waals radius, 1.47 Å) and high electronegativity (3.98 
Pauling scale) endow specific electronic properties that can dramatically alter the biological 
response of the compound [14, 15]. Benzimidazoles, amongst other aza-heterocycles, represent 
privileged substructures in medicinal chemistry and serve as desirable building blocks in the design 
and construction of bioactive compounds [16, 17, 18]. Here we report the synthesis of a number of 
N-fluoroaryl benzimidazole derivatives using SNAr substitution of perfluorinated arenes and the 
screening of these for activity against breast carcinoma MCF-7, leukemia K562, melanoma G361 
and osteosarcoma HOS cell lines. The structures of the fluoroaryl benzimidazole derivatives 
prepared were confirmed by NMR spectroscopy and X-ray crystallographic analysis. 
 
2. Results and Discussion 
2.1 Heterocyclic Synthesis and Characterisation 
Benzimidazole [19, 20, 21] and related azoles [22, 23] are known to add to pentafluoropyridine and 
the aim of this work was to exploit the ready SNAr reaction of benzimidazole derivatives with 
pentafluoropyridine as a building block to make composite linked and fused heterocyclic scaffolds. 
Furthermore, these scaffolds would have potential for further modification to allow synthesis of 
diverse libraries of molecules that can be screened for biological activity. Continuing our interest in 
preparing condensed polycyclic heterarenes from perfluoroarenes [24] we first explored the reaction 
of pentafluoropyridine 2 with 1,3-dihydro-2H-benzimidazole-2-thione 1 (Scheme 1), expecting to 
obtain the tetracylic-fused thiazole 3 by a tandem SNAr addition. The thiolate group of the anion of 
1 was expected to be the most nucleophilic centre and likely to attack C-4 of pentafluoropyridine 
first, leading to the ring fusion shown in 3, if the ring nitrogen then effected a second substitution. 
Similar condensations with aminopyridines to form imidazopyridines have been reported [25]. We 
found however that the thione 1, on treatment with sodium hydride in DMF, reacted instead with 
two molecules of pentafluoropyridine to give the di-arylated benzimidazole 4 in which both the 
sulfur atom and a ring nitrogen of 1 had added to the 4-position of separate pentafluoropyridine 
molecules. Compound 4 was formed even when one equivalent of pentafluoropyridine was used, 
and the best yield of 4 was obtained with three equivalents. Sodium hydride is a convenient base for 
these reactions and can be pre-mixed with the fluoroarene prior to addition of the nucleophile. It 
allows rapid, quantitative deprotonation of the NH group of heterocyclic nucleophiles. The structure 
of compound 4 was supported by 19F-NMR spectroscopy, which exhibited four signals of equal 
intensity (AA’BB’CC’DD’ system) consistent with four pairs of fluorine atoms, rather than three 
signals expected for tetracycle 3. Confirmation of the structure was obtained by single crystal X-ray 
diffraction analysis, and the molecular structure is shown in Figure 1 [26; crystal data in Table 3]. 
Addition of pentafluoropyridine to both ring nitrogen and exocyclic amine groups has also been 
observed with 2-aminopyridine derivatives [27]. 
  
Scheme 1. Reaction of 1,3-dihydro-2H-benzimidazole-2-thione with pentafluoropyridine. 
 
Figure 1. X-ray crystal structure of 4. One of two similar molecules in the asymmetric unit.  
 
Subsequently, we investigated the preparation of linked benzimidazole derivative 5 [28] (Scheme 2) 
as a nucleophilic partner to add to pentafluoropyridine to form tethered heterocyclic scaffolds, as 
linked compounds [29] were of interest due to their potential for acting as bis-intercalating [30, 31] 
and cross linking agents [32, 33, 34] for DNA binding. The bis-benzimidazole 5 (Scheme 2) (X-ray 
structure shown in Figure 2), with a four-methylene spacer chain, reacted readily with excess 
pentafluoropyridine 2, in the presence of sodium hydride, to form 6.  
 
Figure 2. X-ray structure of tetramethylene linked bis-benzimidazole precursor 5. 
 
During initial screening (see section 2.2) compound 6 exhibited good activity against the four 
cancer cell lines studied, and so was pursued as a candidate for further functionalisation. Reactions 
with three amino alcohols and a diamine were investigated with the aim of improving water 
solubility. The amines all reacted at the next most electrophilic position in the tetrafluoropyridine 
rings, adding to C-2, forming the aminopyridine derivatives 7a-d. 
 
Scheme 2. Synthesis of linked benzimidazole-containing scaffolds. 
 
The product derived from addition of ethylenediamine 7d retained good activity against two of the 
cell lines, but was slightly less active against G361 and HOS. Treatment of 6 with the longer 
diamines, 2-(2-aminoethoxy)ethylamine or 2,2'-(ethylenedioxy)bis(ethylamine) surprisingly led to 
macrocycle formation affording compounds 8a and 8b which contain 21- and 24-membered rings 
respectively (Figure 3). Both 14- and 21-membered macrocycles have been formed from 
tetrafluoropyrimidine and pentafluoropyridine previously [35]. The structures of compounds 8a and 
8b were confirmed by X-ray crystallography as shown in Figures 4 and 5. The macrocycle 8a 
formed a mono-ethanol solvate, 8a∙EtOH on recrystallisation, while 8b could be crystallised as the 
hydrate 8b∙2½H2O, or the chloroform solvate 8b∙CHCl3. Diffraction data for 8b∙2½H2O required 
the use of high intensity synchrotron radiation due to small crystal size. Reaction of the linked 
benzimidazole 5 with methyl pentafluorobenzoate afforded 9 with the imidazole nitrogen of 5 
adding para to the ester groups which represent sites for further derivatisation. The X-ray crystal 
structure of the ester compound 9 is shown in Figure 5. 
 
 
Figure 3. Linked and macrocyclic fluoroaryl benzimidazoles. 
 
 
Figure 4. X-ray crystal structure of 8a showing the 21-membered macrocycle with a hydrogen-
bonded ethanol solvate molecule.  
 
Figure 5. X-ray crystal structure of 8b∙2½H2O showing the 24-membered macrocycle with 2½ 
hydrogen bonded water molecules. The molecule lies on a 2-fold axis. O(3) and O(3A) are each ¼ 
occupied.  
 
 
Figure 6. X-ray structure of linked tetrafluorobenzoate scaffold 9. 
 
A further scaffold (Scheme 3) containing tethered benzimidazole units was readily prepared by 
reaction of pentafluorobenzoyl chloride with 2,2'-(ethylenedioxy)bis(ethylamine) forming bis-
amide 10. Reaction with the anion of benzimidazole 11 generated with sodium hydride led to 
substitution of the para fluorine atom in each pentafluorobenzamide ring, affording scaffold 12. 
The structure was confirmed by 1H and 19F NMR spectroscopy. X-ray crystallography was also 
used to confirm the structure of the tethered pentafluorobenzamide 10 (Figure 7). Diffraction data 
for 10 required synchrotron radiation due to small crystal size. 
  
Scheme 3. Reaction of tethered bis-pentafluorobenzamide 10 with benzimidazole. 
 
Figure 7. X-ray structure of amide linked scaffold 10 showing stacked H-bonded 
molecules in a ladder motif. These three molecules comprise the asymmetric unit. 
 
The 19F NMR spectra of the 4-substituted 2,3,5,6-tetrafluoro-aromatic compounds produced 
complex, highly second-order multiplets, that only yielded accurate coupling constants via analysis 
and iterative simulation. It was imperative that the correct sign of coupling constants were explored, 
used and optimised. An excellent starting point was the analysis of 60 MHz (for 1H) NMR spectra 
by Dean and McFarlane [36]. Experimental 19F NMR spectra were obtained on a JEOL-ECS-400 
MHz (for 1H) NMR spectrometer ensuring that sufficient data points were acquired in the FID with 
sufficient signal-to-noise to allow resolution-enhancement by application of a Gaussian function. 
SpinWorks-4 [37] was used to process the FID and simulation/optimisation was achieved using the 
NUMARIT algorithm [38] re-coded to NUMMRIT in C++ by Rudy Sebastian. The 3JFF couplings 
are generally negative (approx. -21 Hz) and the para-5JFF are generally positive (approx. 10 Hz), 
with the 4JFF AA' and BB' couplings generally much smaller and of either sign (approx. ±5 Hz). 
 
Iterative simulation, and manual intervention of the sign of small couplings, allowed 19 assigned 
transitions producing a RMS of 0.217 after three iterations, yielding excellent simulated spectra (see 
supplementary information). For example, analysis of compound 6 produced: AA' = 76.58 
ppm, BB' = 18.44 ppm, 4JAA' = -3.17 ±0.19 Hz, 3JAB = -28.71 ±0.79 Hz, 5JAB' = 19.82 ±0.80 Hz, 
5JA'B = 21.82 ±0.75 Hz, 3JA'B' = -29.30 ±0.73 Hz, 4JBB'  = 14.17 ±0.14 Hz. The ABCX spin system 
for the disubstituted trifluoropyridine derivatives (7, 8) produced a simple set of doublet-of-doublets 
and doublets that yield chemical shifts and couplings directly from the peak-picking values on the 
spectrum. The only uncertainty was the small long-range 4JFH coupling from F-3 to the hydrogen of 
the NH group of the 2-substituent, for which little evidence was available from the 1H NMR and 
which is estimated as ~3Hz. A good match between experimental and simulated NMR spectra was 
achieved for macrocycle 8b: A = 73.96 ppm  (±1 Hz), B = 0.2 ppm (±1 Hz), C = 12.9 ppm (±1 Hz), 
3JFAFB = -31.5 ±1.4 Hz, 5JFAFC = 6.79  ±1.4 Hz, 4JFBFC = 22.9 ±1.4 Hz, 4JFCH = 2.7 ±2 Hz 
(estimated). Analysis of the 13C-19F couplings in 4 is given in the supplementary information. 
 
The ease of such SNAr reactions with a range of benzimidazole nucleophiles demonstrates that this 
synthetic approach can be utilised to rapidly generate libraries of compounds with latent 
functionality for biological screening. The composite heterocycles prepared were then examined for 
anti-cancer activity to identify scaffolds that could be further refined into potential drug candidates. 
 
2.2 Anticancer activity in vitro 
The anticancer activities of all new compounds were determined against several breast 
carcinoma MCF-7 and leukemia K562 cell lines after 72 h of incubation using the Calcein 
assay, and the CDK inhibitor, roscovitine, as a control compound. The results obtained 
(Table 1), show that compounds 4, 6, 7d and 8a display cytotoxicity in which IC50 values 
reached low micromolar ranges.  
 
Table 1. Cytotoxicity of fluoroarylbenzimidazole derivatives. 
 
Compound Cell line IC50 (µM)  K-562 MCF-7 
4 13.2 ± 1.3 >25 
6 2.8 ± 0.4 7.8 ± 2.0 
7a >12.5 >12.5 
7b >12.5 >12.5 
7d 3.4 ± 0.1 8.0 ± 2.6 
7c  >12.5 >12.5 
8a 7.2 ± 1.5 4.8 ± 0.4 
9 >12.5 >12.5 
12 >12.5 >12.5 
roscovitine 42 ± 3 11 ± 1 
 
These four compounds were further screened against melanoma G361 and osteosarcoma 
HOS cell lines to expand information about selectivity towards various types of cancers 
(Table 2). Concentration-dependent activity was observed in all cases with these four 
compounds. Three of the active compounds contained the tetramethylene bis-benzimidazole 
linker group 5 with tri- or tetrafluorinated pyridine rings, whilst the smaller molecule 4 also 
contains two fluorinated pyridine rings, separated by the benzimidazole ring. This suggests 
that two fluorinated pyridine rings separated between 4-6 Å is desirable for activity. Initial 
studies have shown possible interaction with double-stranded DNA with a small increase in 
melting temperature and decrease in fluorescence in ethidium bromide competition 
experiments, but the mechanism of the activity is not yet clear. 
 
Table 2. Cytotoxicity of lead derivatives. 
 
Compound IC50 (µM) 
 G361 HOS 
4 4.4 ± 0.6 2.5 ± 0.9  
6 2.0 ± 0.1 1.8 ± 0.1  
7d 19.9 ± 1.2 16.3 ± 3.0 
8a 6.0 ± 0.1 8.3 ± 2.0  
roscovitine 22.4 ± 0.2 24.3 ± 0.2 
 
 
Further experiments were conducted to gain information about the mechanism underlying 
the observed cytotoxicity. First, we analyzed the effect of compounds 6, 7d and 8a on the 
cell cycle of K562 and MCF-7 cells. Asynchronously growing cells were treated for 24 h 
with compounds in two doses, corresponding to 1× and 3× IC50 values followed by analysis 
via flow cytometry. As shown in Figure 8, the compounds markedly influenced cell cycle 
profiles in both cell lines although each compound demonstrated this effect in a different 
way. Treatment of MCF-7 cells with a low dose of 6 led to a decrease in the S phase, whilst 
a higher dose significantly decreased G1-phase population and increased sub-G1 population 
in both K562 and MCF-7 cell lines. Compound 7d had no effect at the lower dose used, but 
the higher dose significantly increased G2/M population in MCF-7 cells. Interestingly, 
treated K562 cells completely altered the profile, with apparent block of S phase. 
Macrocyclic compound 8a markedly reduced S and G2/M phases in MCF7 cells, while the 
cell cycle profile in K562 was not changed at all. 
 
 
 
 
 
 Figure 8. Effect of studied compounds on the cell cycle of MCF7 and K562 cells treated for 24 h.  
 
Flow cytometric analysis revealed that some compounds increase sub-G1 population, which 
is a well accepted indicator of ongoing apoptotic cell death. We therefore analyzed treated 
K562 cells for activity of caspases 3 and 7, proteases that are activated during apoptotic cell 
death. Figure 9 shows the results of biochemical assay of caspase 3/7 activity in cells treated 
for 24 h with the studied compounds at doses corresponding to 1× and 3× IC50 values. While 
7d was inactive in the assay, compounds 6 and 8a significantly stimulated activation of the 
caspases, with the increase in activity more than twenty-fold, and five-fold, over untreated 
control cells respectively. Based on flow cytometric results and biochemical assay of 
caspases we conclude that 6 and 8a induce apoptosis in treated cells. However, the flow 
cytometric experiments suggest that the active compounds exhibit their toxicity through 
different cellular targets. Further work is ongoing to identify the mode of action of these 
fluorinated compounds. 
 
 
Figure 9. Fluorimetric caspase activity assay. K562 cells treated with studied compounds for 24 h 
were lysed and the activities of caspases were measured using the fluorogenic substrate Ac-DEVD-
AMC and normalised to untreated control. 
 
3. Conclusion 
A library of twelve, structurally diverse, fluoroaryl benzimidazoles was prepared using a simple 
synthetic strategy employing SNAr reactions. This allowed rapid assembly of heterocyclic structures 
containing linked and tethered rings. X-ray crystal structures of seven compounds were obtained 
including those of two macrocyclic compounds containing 21- and 24-membered rings. Three 
compounds 6, 7d and 8a demonstrated micromolar inhibition against K-562 and MCF-7 cell lines. 
These compounds, in addition to 4, also demonstrated micromolar inhibition against G361 and HOS 
cell lines. Compounds 6 and 8a were found to activate caspases leading to apoptosis.  
 
4. Experimental 
4.1 General Methods 
All reactions were conducted under anhydrous conditions using oven/flame-dried glassware under a 
nitrogen atmosphere. Commercially available solvents were used without further purification, 
except THF, which was distilled from sodium and benzophenone. DMF and DMSO were purchased 
dry from a commercial supplier. Light petroleum refers to the fraction boiling between 40-60 °C. 
NMR spectra were recorded (1H, 19F and 13C) using Bruker 500 and 400 MHz, or Jeol ECS-400 
instruments with tetramethylsilane as internal standard or hexafluorobenzene for 19F spectra. 
Chemical shifts are reported in ppm and coupling constants are recorded in hertz. 1H spectra were 
recorded at 400 MHz, 19F spectra at 376 MHz and 13C spectra were recorded at 125 or 100 MHz. 
DEPT was used to assign environment (CH, CH2, CH3) in 13C NMR spectra. The solvent is 
specified in brackets. 
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A Thermofisher Exactive (orbitrap) mass spectrometer was used to obtain high-resolution mass 
spectra, with ESI as the ionization mode. The solvent used for all samples was methanol. Other 
high-resolution mass spectra were recorded at the EPSRC UK National Mass Spectrometry Facility. 
GC-MS was performed on a Fisons 8060 with a DB5MS column of 30 m length and split-less 
injection. 
A Perkin-Elmer spectrum 65FT-IR spectrophotometer was used to obtain infrared spectra. Liquid 
samples were acquired as thin films on NaCl. Solid samples were acquired as KBr discs. 
Melting points were recorded using an Electro thermal-IA 9100 melting point instrument. 
TLC analysis was carried out on Merck TLC silica gel 60 F254 aluminum backed plates and were 
visualised under UV light at 254 nm or by vanillin stain. Column chromatography was carried out 
on Merck Kiesel 60 silica gel.  
Elemental analysis was determined using a Perkin-Elmer 2400 analyser.  
 
4.2. 1-Tetrafluoropyrid-4-yl-2-tetrafluoropyrid-4-ylsulfanyl-1H-benzimidazole 4 
 
A solution of pentafluoropyridine (1.01 g, 6 mmol) in DMF (1.5 mL) was added to NaH (60% 
dispersion in mineral oil) (0.16 g, 4 mmol) and the mixture treated dropwise with a solution of 2-
mercaptobenzimidazole (0.30 g, 2 mmol) in DMF (1.5 mL). The mixture was shaken until gas 
evolution ceased and was then maintained at room temperature for 18 h. The reaction mixture was 
partitioned between ether (25 mL) and water (10 mL). The ether layer was separated, washed with 
water (2 × 2 mL) and saturated NaCl (aq) (2 mL), dried over MgSO4, filtered and evaporated to 
give an off-white solid which was triturated with hexane to give 4 as a cream powder (0.64 g, 78 
%), m.p. 112-115 °C; vmax/cm-1 (film) 1630, 1474, 1246, 975, 952; 𝛿𝛿H (400 MHz, CDCl3) 7.85-7.80 
(1H, m), 7.49-7.45 (2H, m), 7.23-7.19 (1H, m); δC (125 MHz, CDCl3) 144.1 (dtd, 1JCF 248, 2JCF 15, 
4JCF 4), 143.5 (dddd, 1JCF 247, 2JCF 18, 3JCF 13, 4JCF 3), 143.4, 142.0, 141.2 (dm, 1JCF 260), 138.1 
(dm, 1JCF 266), 135.0, 126.1, 126.0 (tt, 2JCF 13, 3JCF 5), 125.0, 124.9 (tt, 2JCF 18, 3JCF 3), 120.7, 
110.1; δF (376 MHz, CDCl3) 77.4-77.1 (2F, AA’), 74.4-74.0 (2F, BB’), 27.0-26.9 (2F, CC’), 19.3-
19.1 (2F, DD’); HRMS (ESI) found m/z 446.9962 (M-H)-, C17H3F8N4S requires 446.9956; Anal. 
(%) calcd for C17H4F8N4S (448): C, 45.55; H, 0.90; N, 12.49; found C, 45.41; H, 0.92; N, 12.00.  
 
4.3. 1,4-bis-1-Tetrafluoropyrid-4-yl-1H-benzimidazol-2-ylbutane 6 
 
A solution of pentafluoropyridine 2 (2.5 g, 15 mmol) in DMSO (2 mL) was added to a stirred 
suspension of sodium hydride NaH (60% dispersion in mineral oil) (0.6 g, 15 mmol) in DMSO (2 
mL). 1,4-bis-1H-Benzimidazol-2-ylbutane 5 [21] (1.45 g, 5 mmol) in DMSO (4 mL) was then 
added dropwise using a syringe pump and the mixture left at room temperature under N2 for 24 h. 
After quenching with a few drops of methanol, distilled water (10 mL) was added, and the 
precipitated solid formed collected by suction filtration to give compound 6 (2.79 g, 95%) as a 
shiny white solid, m.p. 195-198 °C; vmax/cm-1 (film), 2924, 1642, 1471, 1255, 1136, 972, 743; δH 
(400 MHz, CDCl3,) 7.81 (2H, d, 3JHH 7.6), 7.36 (4H, m), 7.07 (2H, d, 3JHH 7.6), 2.87 (4H, m), 2.06 
(4H, m); δC (100 MHz, CDCl3) 153.0, 144.2 (dd, 1JCF 230, 2JCF 26), 142.8, 136.8 (dd, 1JCF 267, 2JCF 
36), 134.2, 127.2-128.1 (m), 124.2, 124.0, 120.1, 109.4, 29.8, 26.4; δF (376 MHz, CDCl3) 76.4-76.1 
(4F, AA’), 18.2-17.9 (4F, BB’); HRMS (ESI) found m/z 589.1376 (MH+), C28H17F8N6 requires 
589.1381; Anal. (%) calcd for C28H16F8N6.½H2O (597): C, 56.28; H, 2.85; N, 14.07; found: C, 
56.38; H, 3.01; N, 13.86. 
 
4.4. 1,4-bis-1-[2-(2-Hydroxyethylamino)-trifluoropyrid-4-yl]-1H-benzimidazol-2-ylbutane 7a 
 
A solution of ethanolamine (0.024 g, 0.4 mmol) in THF (4 mL) was added dropwise to a stirred 
solution of 6 (0.108 g, 0.2 mmol) in THF (4 mL) under N2, and the mixture heated under reflux for 
24 h. Distilled water (10 mL) was added and the mixture was extracted with CH2Cl2 (3 × 20 mL). 
The organic extracts were washed with saturated NaCl (aq) and dried over MgSO4, filtered and 
evaporated to give a white solid (0.14 g). Recrystallisation from ethanol gave 7a as white crystals 
(0.065 g, 50 %), m.p. 175-178 °C; vmax/cm-1 (film), 3425 (N-H), 2947, 1651, 1512, 1427, 1149, 
1057, 987, 748; δH (400 MHz, (CD3)2CO) 7.70 (2H, dd, 3JHH, 8.3, 4JHH 1.6), 7.32-7.25 (6H, m), 
6.60 (2H, s), 4.12 (2H, broad s), 3.78 (4H, t, 3JHH 11.2), 3.60-3.58 (4H, m), 2.88 (4H, m), 1.99 (4H, 
m); δF (376 MHz, CDCl3) 72.5 (2F, t, JFF 26.5), 13.9 (2F, dd, 3JFF 29.6, 4JFF 9.9), 5.1 (2F, dd, 3JFF 
25.5, 4JFF 9.9); HRMS (ESI) found m/z 669.2175 (M-H-), C32H27F6N8O2 requires m/z 669.2161. 
 
4.5. 1,4-bis-1-{2-[2-(2-Hydroxyethoxy)ethylamino)-trifluoropyrid-4-yl]}-1H-benzimidazol-2-
ylbutane 7b 
 
A solution of 2-(2-aminoethoxy)ethanol (0.02 g, 0.2 mmol) in THF (4 mL) was added dropwise to a 
stirred solution of 6 (0.058 g, 0.1 mmol) in THF (4 mL) and the mixture stirred at room temperature 
for 24 h under N2. Distilled water (10 mL) was added and the mixture extracted with ethyl acetate 
(3 × 25 mL). The organic extract was washed with saturated NaCl (aq), dried over MgSO4, filtered 
and evaporated to give a colourless oil (0.07 g). Crystallisation from CH2Cl2 and light petroleum 
gave 7b as white crystals (0.033 g, 42%), m.p. 168-170 °C; vmax/ cm-1 (film), 3333 (N-H), 2870, 
1651, 1512, 1427, 1388, 1273, 1118, 1072, 987, 740; δH (400 MHz, (CD3)2CO) 7.67 (2H, d, 3JHH 
8.0), 7.46 (2H, s), 7.33-7.24 (6H, m), 4.68 (2H, t, 3JHH 4.8), 3.61 (8H, t, 3JHH 5.6), 3.54-3.47 (8H, m 
(overlap with water peak)), 2.78 (4H, m), 1.84 (4H, m); δF (376 MHz, CDCl3) 72.2 (2F, t, JFF 11.7), 
13.6-13.3 (2F, m), −1.93-(−1.46) (2F, m); HRMS (ESI) found m/z 759.2829 (MH+), C36H37F6N8O4 
requires 759.2836. 
 
4.6. 1,4-bis-1-[2-(2,3-Dihydroxypropylamino)-trifluoropyrid-4-yl]-1H-benzimidazol-2-ylbutane 7c 
 
A solution of (±)-3-amino-1,2-propanediol (0.018 g, 0.2 mmol) in DMF (3 mL) was added 
dropwise to a stirred solution of 6 (0.058 g, 0.1 mmol) in THF (3 mL) and the mixture heated at 65 
ᵒC for 24 h under N2. Distilled water (10 mL) was added and the precipitated solid formed collected 
by suction filtration to give 7c as a white solid (0.08 g, 82%), m.p. 123-126 °C; vmax/cm-1 (film), 
3417 (N-H), 2931, 1651, 1427, 1257, 1057, 979, 748; δH (400 MHz, CDCl3) 7.64 (2H, d, 3JHH 7.6), 
7.28-7.18 (6H, m), 4.25 (2H, s), 3.90 (4H, m), 3.84-3.56 (6H, m), 3.47-3.42 (2H, m), 2.90-2.75 (4H, 
m), 1.92-1.86 (4H, m); δF (376 MHz, CDCl3) 72.53 (2F, t, JFF, 26.6), 14.02 (2F, dd, 3JFF 29.1, 4JFF 
8.9), 5.09 (2F, dd, 3JFF 25.4, 4JFF 8.9); HRMS (ESI) found m/z 731.2516 (MH+), C34H33F6N8O4 
requires 731.2523. 
 
4.7. 1,4-bis-1-[2-(2-Aminoethylamino)-trifluoropyrid-4-yl-1H-benzimidazol-2-ylbutane 7d 
 
A solution of ethylenediamine (0.025 g, 0.4 mmol) in THF (2 mL) was added dropwise to stirring 
solution of 6 (0.12 g, 0.2 mmol) in THF (3 mL) and the mixture stirred at room temperature for 24 h 
under N2. Distilled water (10 mL) was added and the mixture extracted with CH2Cl2 (3 × 20 mL). 
The organic extract was dried over MgSO4, filtered and evaporated to give 7d as a white solid (0.11 
g, 85%), m.p. 195-198 °C; vmax/cm-1 (film), 3400 (br. NH), 2095, 1647, 1509, 1453, 1388, 1264; δH 
(400 MHz, CDCl3,) 7.80 (2H, d, 3JHH 7.6), 7.35-7.29 (4H, m), 7.11 (2H, d, 3JHH 7.6), 5.46 (2H, td, 
3JHH 8.4, 4JHF 5.4), 3.57 (4H, dd, 3JHH 11.2, 3JHH 5.2), 3.05 (4H, t, 3JHH 5.6), 2.81 (4H, s), 1.99-1.95 
(4H, m); δF (376 MHz, CDCl3) 72.3 (2F, m), 13.09 (2F, dd, JFF 23.3, JFF 8.6), 1.44 (2F, dd, JFF 23.3, 
JFF 8.6); HRMS (ESI) found m/z 669.2621 (MH+), C32H31F6N10 requires 669.2632. 
 
4.8. Reaction of 1,4-bis-1-tetrafluoropyrid-4-yl-1H-benzimidazol-2-ylbutane 6 with 2-(2-
aminoethoxy)ethylamine: macrocycle 8a 
 
A solution of 2-(2-aminoethoxy)ethylamine (0.07 g, 0. 4 mmol) in THF (3 mL) was mixed with a 
solution of triethylamine (0.08 g, 0.8 mmol) in THF (2 mL) and treated dropwise with a solution of 
6 (0.12 g, 0.2 mmol) in THF (3 mL). The reaction mixture was heated under reflux for 24 h under 
N2. The solvent was evaporated and water (10 mL) was added to the residue, precipitating a yellow 
orange solid, which was filtered, (0.12 g). Column chromatography eluting with ethyl acetate and 
light petroleum (9:1) gave macrocycle 8a as white crystals of the monohydrate (0.04 g, 35 %), m.p. 
203-205 °C; vmax/cm-1 (film) 3434 (N-H), 2099, 1648, 1550, 1453, 1260, 1126, 1011, 744; δH (400 
MHz, CDCl3,) 7.75 (2H, d, 3JHH 8.0), 7.29-7.18 (4H, m), 6.99 (2H, d, 3JHH 8.4), 5.28 (2H, s), 4.05-
4.00 (2H, m), 3.81-3.73 (4H, m), 3.45-3.39 (2H, m), 2.93-2.82 (2H, m), 2.68-2.63 (2H, m), 2.04-
1.87 (4H, m); δC (100 MHz, CDCl3) 153.8, 146.4 (dd, 1JCF 235, 2JCF 14), 142.9, 142.0 (t, 2JCF 13), 
137.8 (dd, 1JCF 255, 2JCF 5), 134.9, 130.7 (dd, 1JCF 254, 2JCF 30), 123.6, 123.3, 123.5-123.0 (m), 
119.9, 109.4, 68.6, 40.6, 27.0, 26.1; δF (376 MHz, CDCl3) 72.6 (2F, dd, JFF 29.5, JFF 23.0), 11.7 
(2F, d, JFF 29.5), 0.55 (2F, dd, JFF 22.5, JFF 8.1); HRMS (ESI) found m/z 653.2196 (MH+), 
C32H27F6N8O requires 653.2207; Anal. (%) calcd for C32H26F6N8O∙H2O (670): C, 57.31; H, 4.17; N, 
16.72; found: C, 57.38 H, 4.18; N, 16.41. 
 
4.9. Reaction of 1,4-bis-1-tetrafluoropyrid-4-yl-1H-benzimidazol-2-ylbutane 6 with 2,2-
(ethylenedioxy)bis(ethylamine): macrocycle 8b  
 
A solution of 2,2-(ethylenedioxy)bis(ethylamine) (0.06 g, 0.4 mmol) in THF (3 mL) was added 
dropwise to stirred solution of compound 6 (0.24 g, 0.4 mmol) in THF (5 mL), and the mixture 
heated under reflux for 24 h under N2. Distilled water (10 mL) was added and the mixture extracted 
with CH2Cl2 (3 × 20 mL). The organic extract was washed with saturated NaCl (aq), dried over 
MgSO4, filtered and evaporated to give a white solid, (0.23 g). Column chromatography eluting 
with ethyl acetate and light petroleum (1:1) gave colourless crystals of 8b dihydrate (0.06 g, 22 %), 
m.p. 133-135 °C; vmax/cm-1 (film) 3311 (N-H), 2925, 2840, 1652, 1508, 1454, 1263, 1097, 990, 744; 
δH (400 MHz, CDCl3) 7.79 (2H, d, 3JHH 7.6), 7.37-7.33 (2H, td, 3JHH 7.2, 4JHH 0.8), 7.30-7.26 (2H, 
td, 3JHH 8.0, 4JHH 1.2), 7.04 (2H, d, 3JHH 7.6), 5.37 (2H, t, 3JHH 4.8), 3.83-3.59 (12H, m), 2.82-2.63 
(4H, m), 2.03-1.87 (4H, m); δF (376 MHz, CDCl3) 72.9 (2F, dd, JFF  29.5, JFF 22.5), 11.95 (2F, d, 
JFF 29.0), -0.74 (2F, dd, JFF 22.5, JFF 8.1); HRMS (ESI) found m/z 697.2462 (MH+), C34H31F6N8O2 
requires 697.2469; Anal. (%) calcd for C34H30F6N8O2∙2H2O (732): C, 55.74; H, 4.64; N, 15.30; 
found: C, 55.88; H, 4.37; N, 14.91. 
 
4.10. 1,4-bis-1-(4-Methoxycarbonyltetrafluorophenyl)-1H-benzimidazol-2-ylbutane 9 
 
A solution of methyl pentafluorobenzoate  (0.452 g, 2 mmol) in DMSO (3 mL) was added to a 
stirred suspension of NaH (60 % dispersion in mineral oil) (0.08 g, 2 mmol) in DMSO (3 mL). A 
solution of 5 (0.29 g, 1 mmol) in DMSO (4 mL) was added dropwise by syringe pump and the 
mixture stirred at room temperature for 24 h under N2. The reaction mixture was quenched by 
dropwise addition of methanol, and distilled water (10 mL) added. A light yellow solid formed and 
was collected by suction filtration, (0.8 g) and recrystallised from ethanol to give 9 as colourless 
crystals (0.41 g, 58 %), m.p. 195-198 °C; vmax/cm-1 (film), 2924, 1642, 1471, 1255, 1136, 972, 743; 
δH (400 MHz, CDCl3,) 7.81 (2H, d, 3JHH 7.6), 7.30-7.38 (m, 4H), 7.04 (2H, d, 3JHH 8.0), 4.09 (6H, 
2), 2.87 (4H, m), 2.06 (4H, m); δC (100 MHz, CDCl3) 159.3, 154.0, 145.4 (dd, 1JCF 263, 2JCF 15), 
142.9, 143.3 (dd, 1JCF 250, 2JCF 15), 135.0, 123.8, 123.5, 119.9, 118.0 (t, 2JCF 15), 114.1 (t, 2JCF 17), 
109.3, 53.8, 27.1, 26.5; δF (376 MHz, CDCl3) 25.3-25.2 (4F, AA’), 19.3-19.2 (4F, BB’); HRMS 
(ESI) found m/z 703.1569 (MH+), C34H23F8N6O4 requires 703.1586. 
 
4.11. 2,2-(Ethylenedioxy)-bis-ethyl  pentafluorobenzamide 10 
 
A stirred solution of 2,2-(ethylenedioxy)-bis-(ethylamine) (0.148 g, 1 mmol) and Et3N (0.202 g, 2 
mmol) in THF (4 mL) was treated dropwise with pentafluorobenzoyl chloride (0.46 g, 2 mmol) in 
THF (2 mL) and the reaction mixture maintained at room temperature under the N2 for 24 h. The 
solvent was evaporated and water (10 mL) added to the residue. A yellow orange solid precipitated, 
and was filtered, (0.5 g). Recrystallisation from CH2Cl2 and light petroleum gave 10 as shiny white 
crystals (0.38 g, 71 %); m.p. 128 - 129 °C; vmax/cm-1 (film), 3279 (N-H), 2872, 1658 (C=O), 1501, 
1135, 1119, 992, 731; δH (400 MHz, CDCl3) 6.55 (2H, s, NH), 3.70-3.66 (8H, m), 2.87 (4H, m); δC 
(100 MHz, CDCl3) 157.6, 144.2 (dd, 1JCF 255, 2JCF 12), 142.3 (dd, 1JCF 260, 2JCF 25), 137.5 (dd, 
1JCF 230, 2JCF 32), 111.5 (t, 2JCF 30), 70.8, 69.8, 40.1; δF (376 MHz, CDCl3) 21.2-21.1 (4F, AA’), 
11.26 (2F, t, 3JFF 20.3), 1.74-1.90 (4F, BB’); HRMS (ESI) found m/z 537.0867 (MH+), 
C20H15F10N2O4 requires 537.0867; Anal. (%) calcd for C20H14F10N2O4 (536): C, 44.79; H, 2.63; N, 
5.22; found: C, 44.78; H, 2.44; N, 5.25. 
 
4.12. 2,2’-(Ethylenedioxy)-bis-ethyl  4-benzimidazol-1-yltetrafluorobenzamide 12 
 
A solution of benzimidazole (0.236 g, 2 mmol) in THF (3 mL) was added dropwise to a stirred 
suspension of NaH (60 % dispersion in mineral oil) (0.08 g, 2 mmol) in THF (3 mL). After 30 min 
a solution of 10 (0.536 g 1 mmol) in THF (3 mL) was added dropwise. The reaction mixture was 
left to stir at room temperature under N2 for 24 h. Distilled water (10 mL) was added and the 
mixture extracted with CH2Cl2 (3 × 25 mL). The organic extract was washed with saturated NaCl 
(aq), dried over MgSO4, filtered and evaporated to give a white solid, (0.65 g). Column 
chromatography eluting with ethyl acetate and methanol (9:1) gave 12 as white crystals (0.4 g, 54 
%); m.p. 115-117 °C; vmax/cm-1 (film) 3194 (N-H), 2877, 166 (C=O), 1550, 1418, 1280, 1134, 987, 
710, 748; δH (400 MHz, CDCl3,) 8.03 (2H, s), 7.91-7.89 (2H, m), 7.43-7.38 (4H, m), 7.22 (2H, d, 
3JHH 6), 7.00 (2H, s), 3.75-3.73 (12H, m); δF (376 MHz, CDCl3) 22.6-22.5 (4F, AA’), 17.8-17.7 
(4F, BB’); HRMS (ESI) found m/z 731.1657 (M-H-), C34H23F8N6O4 requires 731.1659.  
 4.13. Cell Cultures 
Human cancer cell lines MCF-7, K562, G361 and HOS (purchased from the American Type 
Culture Collection) were maintained in DMEM supplemented with 10% fetal bovine serum, 
penicillin (100 U/ml) and streptomycin (100 μg/ml). All cell lines were cultivated at 37 °C 
in 5% CO2 as described previously [39, 40]. 
 
4.14. Cytotoxicity Assays 
The cytotoxicity of the studied compounds was determined as described previously [39, 40]. 
Briefly, cells were assayed with compounds using three-fold dilutions in triplicate. Treatment lasted 
for 72 h, followed by addition of Calcein AM solution and measurement of the fluorescence of live 
cells at 485 nm/538 nm (excitation/emission) with a Fluoroskan Ascent microplate reader 
(Labsystems). The IC50 value, the drug concentration lethal to 50% of the tumor cells, was 
calculated from the obtained dose response curves using GraphPad Prism version 5.0. 
 
4.15. Flow cytometry 
K562 cells (5 × 105 cells/mL) were incubated with test compounds for 24 h. After 
incubation, cells were centrifuged, washed in PBS, fixed with 70% ethanol, washed in PBS 
again, stained with propidium iodide and analysed by flow cytometry using a 488 nm laser 
(Cell Lab Quanta SC, Beckman Coulter).  
 
4.16. Caspase activity assay 
The cells were homogenised in an extraction buffer (10 mM KCl, 5 mM HEPES, 1 mM EDTA, 1 
mM EGTA, 0.2% CHAPS, inhibitors of proteases, pH 7.4) on ice for 20 min. The homogenates 
were clarified by centrifugation at 10000 × g for 30 min at 4 ºC, and then the proteins were 
quantified and diluted to equal concentrations. Lysates were then incubated for 3 h with 100 µM 
Ac-DEVD-AMC as a substrate of caspases 3 and 7 in the assay buffer (25 mM PIPES, 2 mM 
EGTA, 2 mM MgCl2, 5 mM DTT, pH 7.3). The fluorescence of the product was measured using a 
Fluoroskan Ascent microplate reader (Labsystems) at 355/460 nm (excitation/emission) as 
described previously [39, 40]. 
  
Table 3. Crystallographic data for compounds 4, 5, 8a∙EtOH, 8b∙2½H2O, 8b∙CHCl3, 9, and 
10. 
Compound 4 5 8a∙EtOH 8b∙2½H2O 8b∙CHCl3 
Formula C17H4 F8N4S C18H18N4 C32H26F6N8O∙C2H6O C34H30F6N8O2∙2½H2O C34H30F6N8O2∙CHCl3 
Formula weight 448.30 290.36 698.67 741.70 816.03 
Crystal system triclinic orthorhombic monoclinic orthorhombic monoclinic 
Space group Pī Pbca C2/c P21212 P21/n 
Unit cell 
dimensions   
   
a (Å) 9.4800(9) 8.788(3) 14.1373(7) 22.3299(9) 13.8932(16) 
b (Å) 11.4612(11) 9.340(3) 17.2114(8) 6.0739(3) 14.1669(16) 
c (Å) 15.7757(15) 17.743(5) 27.3518(13) 12.2892(5) 18.231(2) 
α (º) 75.3725(14) 90 90 90 90 
β (º) 89.9135(15) 90 103.7199(8) 90 99.7139 
γ (º) 80.8998(15) 90 90 90 90 
V (Å3) 1636.3(3) 1456.3(8) 6465.4(5) 1666.78(13) 3536.8(7) 
Z 4 4 8 2 4 
Temperature (K) 150(2) 150(2) 150(2) 100(2) 150(2) 
Wavelength (Å) 0.71073 0.71073 0.71073 0.7749 0.71073 
Calculated 
density 
(g.cm–3) 
1.820 1.324 1.436 1.478 1.532 
Absorption 
coefficient 
(mm–1) 
0.30 0.08 0.12 0.15 0.34 
Transmission 
factors 
(max./min.) 
0.948 and 0.855 0.988 and 0.914 0.992 and 0.971 0.997 and 0.985 0.888 and 0.839 
Crystal size 
(mm3) 0.54 × 0.43 × 0.18 1.13 × 0.23 × 0.15 0.25 × 0.18 × 0.07 0.10 × 0.03 × 0.02 0.54 × 0.54 × 0.36 
θ(max) (°) 30.6 30.6 28.3 30.8 28.4 
Reflections 
measured 26360 15966 
33520 16401 35615 
Unique 
reflections 9927 2226 
8064 4015 8798 
Rint 0.022 0.047 0.047 0.068 0.051 
Reflections with 
F2 > 2σ(F2) 8270 1773 5498 3344 5995 
Number of 
parameters 573 136 477 278 278 
R1 [F2 > 2σ(F2)] 0.037 0.042 0.042 0.053 0.064 
wR2 (all data) 0.098 0.115 0.101 0.140 0.209 
GOOF, S 1.04 1.05 1.03 1.05 1.02 
Largest 
difference peak 
and hole 
(e Å–3) 
0.46 and –0.45 0.34 and –0.21 0.24 and –0.21 0.29 and –0.38 0.68 and –0.86 
 
Table 3 cont’d. 
 
Compound 9 10 
Formula C34H22F8N4O4 C20H14F10N2 
Formula weight 702.55 536.33 
Crystal system monoclinic monoclinic 
Space group I2/a P21/c 
Unit cell 
dimensions   
a (Å) 19.230(2) 17.4161(6) 
b (Å) 8.3173(10) 14.3221(5) 
c (Å) 38.209(5) 25.7502(9) 
α (º) 90 90 
β (º) 99.650(2) 101.207(2) 
γ (º) 90 90 
V (Å3) 6024.7(12) 6300.5(4) 
Z 8 12 
Temperature (K) 150(2) 150(2) 
Wavelength (Å) 0.71073 0.7749 
Calculated 
density 
(g.cm–3) 
1.549 1.696 
Absorption 
coefficient 
(mm–1) 
0.14 0.17 
Transmission 
factors 
(max./min.) 
0.980 and 0.893 0.998 and 0.992 
Crystal size 
(mm3) 0.85 × 0.40 × 0.15 0.05 × 0.03 × 0.01 
θ(max) (°) 30.6 25.6 
Reflections 
measured 35137 44141 
Unique 
reflections 9202 9083 
Rint 0.038 0.056 
Reflections with 
F2 > 2σ(F2) 6386 6863 
Number of 
parameters 539 991 
R1 [F2 > 2σ(F2)] 0.045 0.055 
wR2 (all data) 0.124 0.142 
GOOF, S 1.05 1.09 
Largest 
difference peak 
and hole 
(e Å–3) 
0.39 and –0.24 0.83 and –0.32 
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